10/580813 '4P9Rec'dPCT/PTO 25 MAY 2006 HUBR-1295-US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s)

Huber, et al.

Serial No.

Please Assign

Filed

•

For

SUBSTANCE BINDING HUMAN IgG Fc RECEPTOR IIb

(FcyRIIb)

Art Unit

•

To be assigned

Examiner

To be assigned

May 22, 2006

Commissioner for Patents P.O. Box 1450

Alexandria, VA 22313-1450

MS: PCT

INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 CFR 1.56, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

These references were cited in the International Search Report of PCT/EP2004/013450 (copy enclosed).

While the information and references disclosed in this Information Disclosure Statement may be "material" pursuant to 37 CFR 1.56, it is not intended to constitute

10/580813 'AP9Rec'dPCT/PTO 25 MAY 2006

an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Commissioner is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 50-0624, under Order No. NY-HUBR-1295-US.

Respectfully submitted

FULBRIGHT & JAWORSKI L.L.P.

James R. Crawford /Reg. No. 39,155

666 Fifth Avenue New York, New York 10103 (212) 318-3000

25657474.1 -2-



PTO/SB/08A (10-01)

Approved for use through 10/31/2002.OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known		
				Application Number		
IN	IFORMATION	DIS	SCLOSURE	Filing Date		
S	TATEMENT E	BY A	PPLICANT	First Named Inventor	Huber et al.	
				Art Unit		
	(use as many she	ets as i	necessary)	Examiner Name		
Sheet	1	of	1	Attorney Docket Number	HUBR-1295-US	

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	

	FOREIGN PATENT DOCUMENTS								
Examiner	Cite	Foreign Patent Document	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant				
Initials*	No.1	Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	1 404 00 1000	Applicant of Cited Document	Passages or Relevant Figures Appear	T ⁸			
	ВА	WO-01/75067 A	10/11/01	Hyseq, Inc.					
	BB	WO-03/054213 A	7/3/03	Genentech, Inc.					
	BC	WO-00/32767 A	6/8/00	Max-Planck-Gesellschaft					
	BD	WO-00/15214 A	3/23/00	Ilexus Pty. Limited					
	BE	WO-99/67293 A	12/29/99	United Biomedical Inc.					
						+1			
	<u> </u>					igspace			
			L	<u>}</u>	<u> </u>	╧			

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

¹Applicant's unique citation designation number (optional). ²See attached Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Examiner Initials	Cite No. 1 Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.				
	CA	Tibbetts, et al. "Linear and Cyclic LFA-1 and ICAM-1 Peptides Inhibit T Cell Adhesion and Function, Peptides, Elsivier			
	СВ	Abstract - Drmanac, et al. "New Isolated Polynucleotide and encoded polypeptides, useful in diagnostics, forensics, gene mapping, identification of mutations responsible for genetic disorders or other traits and to assess biodiversity", Feb. 2002			
			-		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Cyaminas	ID-4-	
Examiner	Date	
Signature	Considered	